Looking for some thoughts on IBRX, because I’m not sure how to read this.
Fintel is showing zero shares available to short, which feels unusual. I’m not assuming a squeeze, but it does suggest new short pressure is limited and borrow is tight.
What I’m trying to figure out is how much that actually matters here. With an FDA-approved drug and real clinical use, the downside case seems capped unless something breaks. On the other hand, without a clear catalyst, this could just drift.
So I’m curious how others see it: Does the lack of shares to short meaningfully change the risk/reward, or is this just noise?